Castle Biosciences develops and commercializes proprietary diagnostic tests that address clinical needs in oncology and gastroenterology. The company's core dermatologic franchise includes DecisionDx-Melanoma for invasive cutaneous melanoma and DecisionDx-SCC for squamous cell carcinoma. In addition to skin cancers, Castle offers DecisionDx-UM for uveal melanoma staging and TissueCypher, a spatial omics test for predicting esophageal cancer risk in patients with Barrett's esophagus. The company operates CLIA-certified laboratory facilities in Phoenix, Arizona, and Pittsburgh, Pennsylvania, where it processes patient tissue samples and delivers test reports directly to healthcare providers. By leveraging genomic information, the company's tests are designed to refine risk stratification beyond traditional clinical and pathology factors.
